Stock Events

Stock Events

Belite Bio 

$150.24
8
-$0.04-0.03% 16:55 Today

Statistics

Day High
150.78
Day Low
146.9
52W High
200
52W Low
97.99
Volume
3,697,414
Avg. Volume
-
Mkt Cap
6.05B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Aug 11Expected
Q3 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
-0.5
-0.33
-0.17
0
Expected EPS
-0.44
Actual EPS
-0.5

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-77.61MNet Income

Analyst Ratings

$251.60Average Price Target
The highest estimate is ⁦303.00⁩.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BLTE. It's not an investment recommendation.
NVIDIA
3
NVDA
Alphabet
3
GOOGL
AMD
3
AMD
Pfizer
3
PFE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals is a leading biotech firm focusing on creating transformative medicines for serious diseases, directly competing with Belite Bio's focus on novel therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, making it a direct competitor in the biotech industry, particularly in areas overlapping with Belite Bio's therapeutic targets.
Biogen
BIIB
Mkt Cap32.49B
Biogen focuses on neurodegenerative diseases, directly competing with Belite Bio's efforts in similar therapeutic areas.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences' strong presence in antiviral and oncology treatments positions it as a competitor to Belite Bio, especially in overlapping disease areas.
AMGEN
AMGN
Mkt Cap217.9B
Amgen's broad focus on innovative human therapeutics makes it a competitor across several of Belite Bio's interest areas, particularly in biologics.
Alnylam Pharmaceuticals
ALNY
Mkt Cap29.4B
Alnylam Pharmaceuticals' work on RNA interference (RNAi) therapeutics for genetic diseases competes with Belite Bio's novel treatment approaches.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical's focus on rare genetic diseases places it in direct competition with Belite Bio, especially in markets targeting niche patient populations.
Novartis
NVS
Mkt Cap268B
Novartis is a global healthcare company with a wide range of pharmaceuticals that compete across multiple therapeutic areas, including those targeted by Belite Bio.
Pfizer
PFE
Mkt Cap158.45B
Pfizer's extensive portfolio in healthcare and pharmaceuticals, including investments in biotechnology and innovation, makes it a broad competitor to Belite Bio.

About

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Show More
CEO
Yu-Hsin Lin
Employees
41
Country
Cayman Islands
ISIN
US07782B1044
WKN
000A3DKYL

Listings

STU
DE
D01.STU
XNAS
US
BLTE
F
DE
D01.F
BOATS
BOATS
BLTE.BOATS

0 Comments

Share your thoughts

FAQs

What is Belite Bio stock price today?▼
The current price of BLTE is $150.24 USD — it has decreased by -0.03% in the past 24 hours. Watch Belite Bio stock price performance more closely on the chart.
What is Belite Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Belite Bio stocks are traded under the ticker BLTE.
Is Belite Bio stock price growing?▼
BLTE stock has risen by +2.34% compared to the previous week, the month change is a -11.21% fall, over the last year Belite Bio has showed a +53.7% increase.
What is Belite Bio market cap?▼
Today Belite Bio has the market capitalization of 6.05B
What were Belite Bio earnings last quarter?▼
BLTE earnings for the last quarter are -0.5 USD per share, whereas the estimation was -0.44 USD resulting in a -13.64% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Belite Bio revenue for the last year?▼
Belite Bio revenue for the last year amounts to 0 USD.
What is Belite Bio net income for the last year?▼
BLTE net income for the last year is -77.61M USD.
How many employees does Belite Bio have?▼
As of October 30, 2026, the company has 41 employees.
In which sector is Belite Bio located?▼
Belite Bio operates in the Health & Wellness sector.
When did Belite Bio complete a stock split?▼
Belite Bio has not had any recent stock splits.
Where is Belite Bio headquartered?▼
Belite Bio is headquartered in San Diego, Cayman Islands.